The effect of immunomodulatory treatment on multiple sclerosis fatique

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 7, 2004, Pages 1045-1047

  Metz, L M ^a,b   Patten, S B ^a   Archibald, C J ^a,b   Bakker, J I ^a,b   Harris, C J ^a,b   Patry, D G ^a,b   Bell, R B ^a,b   Yeung, M ^a,b   Murphy, W F ^a,b   Stoian, C A ^b   Billesberger, K ^b   Tillotson, L ^b   Peters, S ^b   McGowan, D ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; COGNITION DISORDERS; FATIGUE; FEMALE; HUMANS; INTERFERON-BETA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; QUESTIONNAIRES; SICKNESS IMPACT PROFILE;

EID: 3042788175     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2002.007724     Document Type: Article

References (21)

1. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984;65:135-8.
2. Fisk JD, Pontefract A, Ritvo PG, et al. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994;21:9-14.
3. Colosimo C, Millefiorini E, Grasso MG, et al. Fatigue in MS is associated with specific clinical features. Acta Neurol Scand 1995;92:353-5.
4. Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol 1996;9:456-60.
5. Iriarte J, Katsamakis G, De Castro P. The fatigue descriptive scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Mult Scler 1999;5:10-16.
6. Schwartz CE, Coulthard-Morris L, Zeng Q. Psychosocial correlates of fatigue in multiple sclerosis. Arch Phys Med Rehabil 1996;77:165-70.
7. Jackson MF, Quaal C, Reeves MA. Effects of multiple sclerosis on occupational and career patterns. Axone 1991;13:16-22.
8. LaRocca NG. Employment and multiple sclerosis. New York: National Multiple Sclerosis Society health services research reports, 1995:3.
9. Metz LM, Patten SB, McGawan. Symptomatic therapies of multiple sclerosis. Biomed Pharmacother 1999;53:371-9.
10. Krupp LB, Rizvi SA. Symptomatic therapy for underrecognized manifestations of multiple sclerosis. Neurology 2002 Apr 23;58(suppl 4):S32-9.
11. Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994;18:S79-83.
12. The IFBN Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
13. The PRISMS Study Group. Randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-504.
14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76.
15. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
16. Gillson G, Richard TL, Smith RB, et al. A double-blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis. Mult Scler 2002;8:30-5.
17. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002;72:179-83.
18. Mathiowetz V, Matuska KM, Murphy ME. Efficacy of an energy conservation course for persons with multiple sclerosis. Arch Phys Med Rehabil 2001;82:449-56.
19. Hautecoeur P, Forzy G, Gallois P, et al. Variations of IL2, IL6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol Belg 1997;97:240-3.
20. Brod SA, Marshall GD, Henninger EM, et al. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases inferleukin-6 production in multiple sclerosis. Neurology 1996;46:1633-8.
21. Martinez-Caceres EM, Rio J, Barrau M, et al. Amelioration of flu-like symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. Ann Neurol 1998;44:682-5.